Glutaminase Antagonist

6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity.

JHU-083, a proagent of 6-diazo-5-oxo-L-norleucine (DON; HY-108357), is an orally active and selective glutaminase antagonist. JHU-083 blocks glutaminase activity in brain CD11b⁺ cells and experimental cerebral malaria (ECM) resulting in a net decrease of glutamate levels in the animals.

Duazomycin A is a glutamine antagonist. Duazomycin A can significantly enhance the effectiveness of 6-Mercaptopurine (6-MP) (HY-13677) in experimental allergic encephalomyelitis (EAE) without increasing toxicity.

Duazomycin (Duazomycin A) sodium is a glutamine antagonist. Duazomycin sodium can significantly enhance the effectiveness of 6-Mercaptopurine (6-MP) (HY-13677) in experimental allergic encephalomyelitis (EAE) without increasing toxicity.

6-Diazo-5-oxo-L-nor-Leucine (Standard) is the analytical standard of 6-Diazo-5-oxo-L-nor-Leucine. This product is intended for research and analytical applications. 6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) is a glutamine antagonist that irreversibly inhibits the catabolic effect of glutamine. 6-Diazo-5-oxo-L-nor-Leucine shows good anticancer activity (especially in pancreatic cancer) and reduces the self-renewal potential and metastatic capacity of tumour cells. 6-Diazo-5-oxo-L-nor-Leucine also possesses antibacterial and antiviral activity[1][2][3].

Duazomycin sodium (Standard) is the analytical standard of Duazomycin sodium (HY-105723A). This product is intended for research and analytical applications. Duazomycin (Duazomycin A) sodium is a glutamine antagonist. Duazomycin sodium can significantly enhance the effectiveness of 6-Mercaptopurine (6-MP) (HY-13677) in experimental allergic encephalomyelitis (EAE) without increasing toxicity.